Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma

Pancreas

Volumn 43, Issue 7, 2014, Pages 1032-1041

  Tomita, Yasuhiko ^a   Azuma, Kanako ^b   Nonaka, Yuji ^b   Kamada, Yoshihiro ^b   Tomoeda, Miki ^a   Kishida, Mioka ^a   Tanemura, Masahiro ^c   Miyoshi, Eiji ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Alcoholic fatty pancreas disease (AFPD); Chronic pancreatitis (CP); Fatty degeneration; Fibrosis; Inflammatory cell infiltration; Nonalcoholic fatty pancreas disease (NAFPD)

Indexed keywords

PANCREATIC ELASTASE;

ADIPOSE TISSUE; ADJUVANT THERAPY; ADULT; AGED; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; CHEMORADIOTHERAPY; CHRONIC PANCREATITIS; COMORBIDITY; COMPLICATION; DISEASE COURSE; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; FIBROSIS; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; PANCREAS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OBESITY; PANCREAS; PANCREATECTOMY; PANCREATIC ELASTASE; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PRECANCEROUS CONDITIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84914102613     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000159     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CACancer J Clin. 2013;63:11-30.
2. Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998;10:362-366.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
4. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846-2850.
5. Nagata S, Jin YF, Yoshizato K, et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol. 2009;16:2531-2538.
6. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433-1437.
7. Talamini G, Falconi M, Bassi C, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol. 1999;94:1253-1260.
8. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51:849-852.
9. Ammann RW. A clinically based classification system for alcoholic chronic pancreatitis: summary of an international workshop on chronic pancreatitis. Pancreas. 1997;14:215-221.
10. Sarles H. Definitions and classifications of pancreatitis. Pancreas. 1991;6:470-474.
11. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252-1261.
12. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007;9:312-318.
13. van Geenen EJ, Smits MM, Schreuder TC, et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas. 2010;39:1185-1190.
14. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
15. Panozzo MP, Basso D, Plebani M, et al. Effects of pancreaticobiliary duct obstruction on the exocrine and endocrine rat pancreas. Pancreas. 1995;11:408-414.
16. Kloppel G, Detlefsen S, Feyerabend B. Fibrosis of the pancreas: the initial tissue damage and the resulting pattern. Virchows Arch. 2004;445:1-8.
17. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454-467.
18. Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010;32:128-131.
19. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766-781.
20. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66-74.
21. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58:1410-1418.
22. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2011;140:850-856.
23. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010;16:5028-5037.
24. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946-954.
25. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16:771-783.
26. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175-2181.
27. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986-990.
28. Dobrila-Dintinjana R, Vanis N, Dintinjana M, et al. Etiology and oncogenesis of pancreatic carcinoma. Coll Antropol. 2012; 36:1063-1067.
29. Shirakawa T, Kusaka Y, Morimoto K. Combined effect of smoking habits and occupational exposure to hard metal on total IgE antibodies. Chest. 1992;101:1569-1576.
30. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143:550-563.
31. Baumgart S, Ellenrieder V, Fernandez-Zapico ME. Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut. 2013;62:310-316.
32. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837-858.
33. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis. 2012;16:659-666.
34. Lohr M, Kloppel G, Maisonneuve P, et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005;7:17-23.
35. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:2085-2093.
36. Vonlaufen A, Phillips PA, Xu Z, et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res. 2008; 68:7707-7710.
37. Xu Z, Vonlaufen A, Phillips PA, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol. 2010;177:2585-2596.
38. Apte M, Pirola R, Wilson J. The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells. Antioxid Redox Signal. 2011;15:2711-2722.
39. Samkharadze T, Erkan M, Reiser-Erkan C, et al. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am J Gastroenterol. 2011;106:968-980.
40. Phillips PA, Yang L, Shulkes A, et al. Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion. Proc Natl Acad Sci U S A. 2010;107:17397-17402.
41. Vonlaufen A, Phillips PA, Yang L, et al. Isolation of quiescent human pancreatic stellate cells: a promising in vitro tool for studies of human pancreatic stellate cell biology. Pancreatology. 2010; 10:434-443.
42. Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291-302.
43. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
44. Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol. 2011;8:169-177.
45. Hirota M, Shimosegawa T, Masamune A, et al. The sixth nationwide epidemiological survey of chronic pancreatitis in Japan. Pancreatology. 2012;12:79-84.
46. Yadav D, Timmons L, Benson JT, et al. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Am J Gastroenterol. 2011;106:2192-2199.
47. Yoneda M, Mawatari H, Fujita K, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008; 40:371-378.
48. Yin M, Chen J, Glaser KJ, et al. Abdominal magnetic resonance elastography. Top Magn Reson Imaging. 2009;20:79-87.
49. Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol. 2010;16:966-972.